Following the ASCO-GI annual meeting, Nephron hosted a discussion with two key opinion leaders to discuss the latest innovation in diagnostics for colorectal cancer (CRC). Topics of discussion included adoption of non-invasive diagnostics for colorectal cancer screening, such as Cologuard and liquid biopsy. In addition, we discussed the latest data updates from Exact Sciences for Cologuard 2.0, and how emerging entrants in liquid biopsy stack up in the testing paradigm. Finally, we discussed the latest updates in minimal residual disease (MRD) testing and recurrence monitoring in clinical practice for treatment of GI cancers.